Company: PRME
Filing Date: 2025-07-14
Form Type: DEF 14A
Source: 0001193125-25-158716
Chunk: 7

Company: Prime Medicine, Inc.
Filing Date: 2025-07-14
Form: DEF 14A
Chunk 7
---
 a broker, bank or other nominee rather than directly in their own name. If you hold your shares in
one of these ways, you are considered a beneficial owner of shares held in “street name,” not a record owner, and you therefore have no direct vote on any matter to come before the Special Meeting. Your broker, bank or other nominee will
send you voting instructions for you to use in directing the broker, bank or other nominee in how to vote your shares. Your broker, bank or other nominee may allow you to deliver your voting instructions via the telephone or the Internet. Therefore,
we urge you to carefully review and follow the voting instruction form and any other materials that you receive from that organization. If you hold your shares in multiple accounts, you should vote your shares as described in each set of proxy
materials you receive.

A “broker non-vote” occurs when a broker, bank or other nominee
holding shares for a beneficial owner does not vote the shares on a proposal because the broker, bank or other nominee does not have discretionary voting power for a particular item and has not received instructions from the beneficial owner
regarding voting. The New York Stock Exchange (“NYSE”) has rules that govern brokers who have record ownership of listed company stock (including stock such as ours that is listed on The Nasdaq Global Market) held in brokerage accounts for
their clients who beneficially own the shares. Under the rules of NYSE, brokers, banks or other nominees who hold shares for the accounts of their clients have discretionary authority to vote shares if specific instructions are not given with
respect to “routine” matters.

Although the determination of whether a broker, bank or other nominee will have discretionary
voting power for a particular item is typically determined only after proxy materials are filed with the SEC, we expect that the approval of the repricing of certain outstanding stock options that have been granted under the 2019 Plan and/or the
2022 Plan (Proposal 1) and the approval of a proposal to adjourn the Special Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of additional proxies in the event that there are insufficient votes for, or
otherwise in connection with, the approval of the Option Repricing Proposal at the time of the Special Meeting (Proposal 2) will be non-routine matters. Accordingly, if you hold your shares through a broker,
bank or other nominee and you do not timely provide your broker, bank or other nominee with specific instructions on how to vote your shares